Insider Selling: Cryoport, Inc. (NASDAQ:CYRX) CEO Sells $29,059.80 in Stock

Cryoport, Inc. (NASDAQ:CYRX) CEO Jerrell Shelton sold 4,620 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $6.29, for a total transaction of $29,059.80. Following the completion of the sale, the chief executive officer now owns 765,399 shares in the company, valued at $4,814,359.71. This represents a 0.60 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Jerrell Shelton also recently made the following trade(s):

• On Monday, March 10th, Jerrell Shelton sold 4,173 shares of Cryoport stock. The shares were sold at an average price of $4.88, for a total value of $20,364.24.

Cryoport Stock Down 1.2 %

Shares of NASDAQ:CYRX opened at $5.77 on Friday. The company has a current ratio of 5.70, a quick ratio of 5.32 and a debt-to-equity ratio of 0.48. The firm has a market cap of $287.98 million, a price-to-earnings ratio of -1.71 and a beta of 1.67. The stock’s 50-day moving average price is $6.86 and its two-hundred day moving average price is $7.41. Cryoport, Inc. has a 12-month low of $4.58 and a 12-month high of $20.11.

Cryoport (NASDAQ:CYRX) last released its earnings results on Tuesday, March 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.09). Cryoport had a negative return on equity of 13.35% and a negative net margin of 70.08%. The company had revenue of $59.53 million during the quarter, compared to analyst estimates of $58.71 million. During the same period in the prior year, the business posted ($0.29) earnings per share. On average, research analysts forecast that Cryoport, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on CYRX shares. Guggenheim assumed coverage on Cryoport in a report on Thursday, December 19th. They issued a “buy” rating and a $11.00 price target for the company. Needham & Company LLC reiterated a “buy” rating and set a $11.00 price target on shares of Cryoport in a report on Wednesday, March 5th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Institutional Trading of Cryoport

Several institutional investors have recently made changes to their positions in CYRX. Quest Partners LLC boosted its holdings in Cryoport by 168.5% in the third quarter. Quest Partners LLC now owns 29,083 shares of the company’s stock valued at $236,000 after acquiring an additional 18,252 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Cryoport in the 3rd quarter worth about $326,000. Intech Investment Management LLC acquired a new position in shares of Cryoport in the 3rd quarter valued at about $105,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Cryoport by 0.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 387,714 shares of the company’s stock worth $3,144,000 after purchasing an additional 2,226 shares during the period. Finally, Algert Global LLC increased its position in Cryoport by 282.7% during the 3rd quarter. Algert Global LLC now owns 247,483 shares of the company’s stock worth $2,007,000 after purchasing an additional 182,808 shares in the last quarter. 92.90% of the stock is owned by hedge funds and other institutional investors.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.